AIMS: Electronic health records (EHRs) are essential in improving quality and enhancing efficiency of health-care delivery. By 2015, medical care receiving service reimbursement from US Centers for Medicare and Medicaid Services (CMS) must show 'meaningful use' of EHRs. Substance use disorders (SUD) are grossly under-detected and under-treated in current US medical care settings. Hence, an urgent need exists for improved identification of and clinical intervention for SUD in medical settings. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) has leveraged its infrastructure and expertise and brought relevant stakeholders together to develop consensus on brief screening and initial assessment tools for SUD in general medical settings, with the objective of incorporation into US EHRs. METHODS: Stakeholders were identified and queried for input and consensus on validated screening and assessment for SUD in general medical settings to develop common data elements to serve as shared resources for EHRs on screening, brief intervention and referral to treatment (SBIRT), with the intent of supporting interoperability and data exchange in a developing Nationwide Health Information Network. RESULTS: Through consensus of input from stakeholders, a validated screening and brief assessment instrument, supported by Clinical Decision Support tools, was chosen to be used at out-patient general medical settings. CONCLUSIONS: The creation and adoption of a core set of validated common data elements and the inclusion of such consensus-based data elements for general medical settings will enable the integration of SUD treatment within mainstream health care, and support the adoption and 'meaningful use' of the US Office of the National Coordinator for Health Information Technology (ONC)-certified EHRs, as well as CMS reimbursement. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: Electronic health records (EHRs) are essential in improving quality and enhancing efficiency of health-care delivery. By 2015, medical care receiving service reimbursement from US Centers for Medicare and Medicaid Services (CMS) must show 'meaningful use' of EHRs. Substance use disorders (SUD) are grossly under-detected and under-treated in current US medical care settings. Hence, an urgent need exists for improved identification of and clinical intervention for SUD in medical settings. The National Institute on Drug Abuse Clinical Trials Network (NIDA CTN) has leveraged its infrastructure and expertise and brought relevant stakeholders together to develop consensus on brief screening and initial assessment tools for SUD in general medical settings, with the objective of incorporation into US EHRs. METHODS: Stakeholders were identified and queried for input and consensus on validated screening and assessment for SUD in general medical settings to develop common data elements to serve as shared resources for EHRs on screening, brief intervention and referral to treatment (SBIRT), with the intent of supporting interoperability and data exchange in a developing Nationwide Health Information Network. RESULTS: Through consensus of input from stakeholders, a validated screening and brief assessment instrument, supported by Clinical Decision Support tools, was chosen to be used at out-patient general medical settings. CONCLUSIONS: The creation and adoption of a core set of validated common data elements and the inclusion of such consensus-based data elements for general medical settings will enable the integration of SUD treatment within mainstream health care, and support the adoption and 'meaningful use' of the US Office of the National Coordinator for Health Information Technology (ONC)-certified EHRs, as well as CMS reimbursement. Published 2012. This article is a U.S. Government work and is in the public domain in the USA.
Authors: Leigh Anne Tang; Alvin D Jeffery; Ashley A Leech; Sarah S Osmundson; Lori Schirle; Julia C Phillippi Journal: Am J Obstet Gynecol MFM Date: 2021-11-19
Authors: Li-Tzy Wu; Kathleen T Brady; Susan E Spratt; Ashley A Dunham; Brooke Heidenfelder; Bryan C Batch; Robert Lindblad; Paul VanVeldhuisen; Shelley A Rusincovitch; Therese K Killeen; Udi E Ghitza Journal: Contemp Clin Trials Date: 2015-11-10 Impact factor: 2.226
Authors: Mikko Sayre; Gwen T Lapham; Amy K Lee; Malia Oliver; Jennifer F Bobb; Ryan M Caldeiro; Katharine A Bradley Journal: J Gen Intern Med Date: 2020-01-23 Impact factor: 5.128
Authors: Giovanni Serpelloni; Maurizio Gomma; Bruno Genetti; Monica Zermiani; Claudia Rimondo; Roberto Mollica; Jan Gryczynski; Kevin E O'Grady; Robert P Schwartz Journal: J Subst Abuse Treat Date: 2013-03-19
Authors: Ana Ventuneac; Gavriella Hecht; Emily Forcht; Bianca A Duah; Shafaq Tarar; Blanche Langenbach; Jay Gates; Demetria Cain; H Jonathon Rendina; Judith A Aberg; David C Perlman Journal: Front Sociol Date: 2021-05-18